Valneva stock
VLA.PAPARValneva SE, HealthcareISIN FR0004056851
31Score 31 out of 100, Weak
Price and trend
59 / 100
Price history
−33% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 8.1% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 48% below its 52-week high. Largest decline in 19 years: 94% (November 2021 to December 2024).
Chart figures for advanced users
- SMA 50$2.94
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.31
- The lowest closing price of the last twelve months.
- Resistance$5.65
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Valneva SE belongs to the Biotechnology industry (France) and, with a market value of $556.76M, is number 235 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $194.34M (up 3% year on year) and a loss of $128.17M.
- For fiscal 2026, analysts expect on average revenue of $168.82M (down 13.1%) and adjusted earnings per share of −$0.50.
Show more
- MEQIRI Score 31 out of 100 (Weak): rank 687 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 85% since 2020.Capital allocation 18
- High debtDebt 2.59 times equity (latest quarter), Biotechnology median 0.09.Stability 30
- Loss-makingLoss of $175.42M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 28 to 31.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 27.2% on the twelve months before. Revenue has grown strongly since 2006, at around 26% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 39%, operating −47%, net −66%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Nov 2026in 12 days
- Last reported
- 13 Aug 2026EPS reported −$0.19 (expected −$0.10)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.500.0%
- Revenue
- $168.82M−0.1%
- Earnings per share
- $0.310.0%
- Revenue
- $322.97M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +22.0%2026 guidance confirmed: product sales of EUR 135 million to EUR 150 million and total revenues of EUR 145 million to EUR 160 million.
“We confirm our financial guidance for the fiscal year 2026 with product sales of EUR 135 million to EUR 150 million and total revenues of EUR 145 million to EUR 160 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Valneva
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 31
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Monopar TherapeuticsMNPR $612.75M42
- GenfitGNFT.PA $609.09M44
- Helus PharmaHELP $582.03M40
- Adlai NortyeANL $575.92M36
- Entera BioENTX $560.72M44
- REGENXBIORGNX $560.06M32
- Crescent BiopharmaCBIO $548.24M33
- Ovid TherapeuticsOVID $542.93M44
ETFs that hold Valneva
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.05% | 0.40% | €1.49B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.